CSIMarket
 
Intercept Pharmaceuticals inc   (ICPT)
Other Ticker:  
 
 
Price: $19.0000 $0.04 0.211%
Day's High: $19.01 Week Perf: 0.21 %
Day's Low: $ 18.98 30 Day Perf: 1.99 %
Volume (M): 3,963 52 Wk High: $ 19.39
Volume (M$): $ 75,305 52 Wk Avg: $13.71
Open: $19.00 52 Wk Low: $8.82



 Market Capitalization (Millions $) 794
 Shares Outstanding (Millions) 42
 Employees 452
 Revenues (TTM) (Millions $) 288
 Net Income (TTM) (Millions $) -62
 Cash Flow (TTM) (Millions $) -17
 Capital Exp. (TTM) (Millions $) 0

Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases. The company was founded in 2002 by Mark Pruzanski and is headquartered in New York City, with additional offices in London and San Diego. The company is publicly traded under the symbol ICPT on the NASDAQ stock exchange.

Intercept's flagship product is Ocaliva (obeticholic acid), which was approved by the US Food and Drug Administration (FDA) in 2016 for the treatment of primary biliary cholangitis (PBC), a rare and chronic autoimmune liver disease. Ocaliva is the first and only drug approved for the treatment of PBC in over 20 years. In 2019, Ocaliva was also approved in the European Union for the treatment of PBC.

In addition to PBC, Intercept has a pipeline of drug candidates under development for the treatment of nonalcoholic steatohepatitis (NASH), a fatty liver disease that can lead to liver damage, cirrhosis and cancer. NASH affects millions of people worldwide and is a major cause of liver-related morbidity and mortality. Intercept's most advanced NASH candidate is called obeticholic acid (OCA), which is being evaluated in several clinical trials.

Intercept's research and development efforts are focused on discovering and developing new drugs that target the underlying mechanisms of liver disease. The company leverages its expertise in liver biology, drug discovery and development, and clinical research to advance its pipeline of drug candidates. Intercept has collaborations and partnerships with leading academic institutions, research organizations, and pharmaceutical companies to enhance its research capabilities and bring new therapies to the market.

Intercept has received numerous awards and recognitions for its contributions to the biopharmaceutical industry and research in liver disease. The company is committed to creating value for patients, healthcare providers, and shareholders, and is well positioned for continued growth and success in the years to come.


   Company Address: 305 Madison Avenue, Morristown 7960 NJ
   Company Phone Number: 747-1000   Stock Exchange / Ticker: NASDAQ ICPT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals Inc: A Surprising Twist - Strong Revenue Puzzles Experts, But Profitability Remains Elusive



Intercept Pharmaceuticals Inc., a major player in the pharmaceutical industry, has experienced a slight increase in its stock performance over the last five trading days. With a year-to-date performance of 51.48%, the company has outperformed its industry peers. Furthermore, Intercept Pharmaceuticals Inc. shares are currently trading significantly above its 52-week average on NASDAQ. In this article, we will delve into the recent financial results of Intercept Pharmaceuticals Inc., examining how they may impact the company moving forward.
Revenue Growth:
In the period from July to September 2023, Intercept Pharmaceuticals Inc. witnessed a commendable increase in revenue, amounting to $88.79 million, representing a growth of 14.437% in comparison to the corresponding reporting season the previous year. This surge in revenue outpaces the rest of the Major Pharmaceutical Preparations industry, which reported an average revenue increase of 3.18% during the same period. Intercept Pharmaceuticals Inc.'s ability to outperform its industry peers in terms of top-line growth highlights its strength in the market.

Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals Reports Impressive Leap in Q2 2023 Earnings and 16.669% Revenue Boost

The stock market has always been an exciting and lucrative venture for investors, and with the recent financial results from Intercept Pharmaceuticals Inc, there is plenty of reason to be pleased. The company's performance for the April to June 30, 2023 financial period has shown significant improvements in various key metrics, indicating a positive future for the stock.
Firstly, let's talk about the earnings per share. Intercept Pharmaceuticals Inc managed to decrease its loss per share from $-0.25 to $-0.14 compared to the same period last year. This is a commendable achievement and showcases the company's ability to streamline its operations and optimize its financial performance. Additionally, the earnings per share also improved from $-0.77 in the preceding reporting period, further reinforcing the positive trajectory of the company.






 

Intercept Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com